Stock listing
Xetra:NVV1 Novavax, Inc. Aktie
German listing (Xetra) of Novavax, Inc. · home listing NASDAQ:NVAX
Follow Novavax, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:NVAX
$7.47 USD -0.49 (-6.2%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:NVAX
- Day range
- $7.43 – $7.98 USDNov 20, 2026
- Volume
- 4.73M sharesNov 20, 2026
- Market cap
- $1.23B USDAt the close on Nov 20, 2026 · price × 165.0M shares outstanding
- 52-week range
- $6.25 – $13.39 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $71.06M USDMedian day 5.89M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:NVAX · Home | $7.47 USD | -0.49 (-6.2%) | 4,731,111 | $7.59 | $7.98 | $7.43 | $7.96 | Close on Nov 20, 2026 |
| Frankfurt:NVV1 | €6.89 EUR | -0.39 (-5.4%) | 2,620 | €6.96 | €7.10 | €6.89 | €7.28 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:NVAX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $7.47 | -0.49 | -6.2% | $7.59 | $7.98 | $7.43 | 4,731,111 | |
| $7.96 | 0.00 | 0.0% | $7.90 | $8.32 | $7.85 | 4,242,884 | |
| $7.96 | -0.10 | -1.2% | $8.09 | $8.14 | $7.88 | 3,529,883 | |
| $8.06 | -0.465 | -5.5% | $8.302 | $8.42 | $7.98 | 4,722,291 | |
| $8.525 | -0.235 | -2.7% | $8.76 | $8.785 | $8.35 | 4,636,716 | |
| $8.76 | -1.22 | -12.2% | $9.73 | $9.74 | $8.75 | 6,980,800 | |
| $9.98 | -0.22 | -2.2% | $10.28 | $10.36 | $9.895 | 5,892,699 | |
| $10.20 | -0.69 | -6.3% | $10.61 | $10.71 | $10.07 | 12,255,121 | |
| $10.89 | +0.11 | +1.0% | $10.83 | $11.20 | $10.42 | 8,491,763 | |
| $10.78 | +1.00 | +10.2% | $10.06 | $10.93 | $9.995 | 6,284,091 | |
| $9.78 | -0.87 | -8.2% | $10.34 | $10.68 | $9.465 | 8,199,553 | |
| $10.65 | +0.97 | +10.0% | $10.01 | $10.67 | $9.84 | 5,958,391 | |
| $9.68 | +0.15 | +1.6% | $9.555 | $9.95 | $9.45 | 3,461,748 | |
| $9.53 | -0.55 | -5.5% | $10.11 | $10.38 | $9.485 | 4,077,126 | |
| $10.08 | -0.39 | -3.7% | $10.29 | $10.65 | $9.915 | 4,059,377 | |
| $10.47 | +0.15 | +1.5% | $10.22 | $10.62 | $10.19 | 2,788,557 | |
| $10.32 | +0.30 | +3.0% | $9.81 | $10.34 | $9.74 | 4,742,915 | |
| $10.02 | +0.62 | +6.6% | $9.37 | $10.10 | $8.95 | 6,766,791 | |
| $9.40 | -0.30 | -3.1% | $9.52 | $9.88 | $9.26 | 4,916,371 | |
| $9.70 | -0.29 | -2.9% | $9.84 | $9.93 | $9.62 | 4,415,600 | |
| $9.99 | -1.02 | -9.3% | $10.79 | $10.87 | $9.56 | 12,251,500 | |
| $11.01 | -0.42 | -3.7% | $11.39 | $11.46 | $10.99 | 5,440,600 | |
| $11.43 | +0.61 | +5.6% | $10.75 | $11.57 | $10.55 | 6,526,400 | |
| $10.82 | -0.44 | -3.9% | $11.20 | $11.99 | $10.76 | 6,206,000 | |
| $11.26 | -1.56 | -12.2% | $12.71 | $12.84 | $11.11 | 9,891,800 | |
| $12.82 | +0.18 | +1.4% | $12.50 | $13.25 | $12.18 | 7,366,900 | |
| $12.64 | -0.18 | -1.4% | $12.69 | $13.34 | $12.57 | 8,545,800 | |
| $12.82 | +0.16 | +1.3% | $12.44 | $13.13 | $12.21 | 8,395,500 | |
| $12.66 | -0.09 | -0.7% | $12.61 | $12.96 | $12.19 | 8,501,800 | |
| $12.75 | +1.74 | +15.8% | $11.17 | $13.04 | $11.03 | 19,026,400 | |
| $11.01 | -0.21 | -1.9% | $11.01 | $11.18 | $10.76 | 6,208,300 | |
| $11.22 | -0.10 | -0.9% | $11.01 | $11.75 | $10.90 | 8,381,200 | |
| $11.32 | -1.24 | -9.9% | $12.35 | $13.33 | $10.88 | 19,413,000 | |
| $12.56 | +2.10 | +20.1% | $10.47 | $13.39 | $10.28 | 28,701,900 | |
| $10.46 | -0.14 | -1.3% | $10.80 | $10.86 | $10.33 | 4,023,000 | |
| $10.60 | -0.21 | -1.9% | $10.75 | $10.98 | $10.55 | 3,147,200 | |
| $10.81 | -0.01 | -0.1% | $10.85 | $11.10 | $10.54 | 4,564,400 | |
| $10.82 | +0.02 | +0.2% | $10.80 | $11.11 | $10.41 | 4,069,300 | |
| $10.80 | +0.17 | +1.6% | $10.50 | $10.98 | $10.26 | 4,455,800 | |
| $10.63 | +0.03 | +0.3% | $10.62 | $10.79 | $10.34 | 3,909,900 | |
| $10.60 | +0.05 | +0.5% | $10.43 | $10.85 | $10.38 | 4,353,200 | |
| $10.55 | -0.28 | -2.6% | $10.79 | $10.95 | $10.47 | 5,767,200 | |
| $10.83 | +0.42 | +4.0% | $10.39 | $11.09 | $10.15 | 7,578,400 | |
| $10.41 | +0.30 | +3.0% | $10.38 | $10.70 | $10.21 | 6,131,800 | |
| $10.11 | +0.11 | +1.1% | $9.89 | $10.15 | $9.76 | 11,143,300 | |
| $10.00 | +0.65 | +7.0% | $9.62 | $10.38 | $9.61 | 8,873,000 | |
| $9.35 | +0.12 | +1.3% | $9.35 | $9.41 | $9.16 | 2,847,700 | |
| $9.23 | -0.36 | -3.8% | $9.50 | $9.56 | $9.16 | 3,328,500 | |
| $9.59 | +0.17 | +1.8% | $9.38 | $9.60 | $9.14 | 3,364,900 | |
| $9.42 | +0.12 | +1.3% | $9.29 | $9.87 | $9.23 | 6,115,700 | |
| $9.30 | -0.55 | -5.6% | $9.64 | $9.68 | $9.11 | 5,887,700 | |
| $9.85 | -0.34 | -3.3% | $10.02 | $10.24 | $9.73 | 4,437,500 | |
| $10.19 | -0.03 | -0.3% | $10.10 | $10.36 | $9.75 | 4,228,900 | |
| $10.22 | -0.12 | -1.2% | $10.50 | $10.75 | $10.05 | 5,123,200 | |
| $10.34 | +0.02 | +0.2% | $10.42 | $10.48 | $9.90 | 6,226,600 | |
| $10.32 | +0.20 | +2.0% | $10.28 | $10.73 | $9.96 | 5,635,800 | |
| $10.12 | +0.75 | +8.0% | $9.20 | $10.26 | $9.19 | 10,040,600 | |
| $9.37 | +0.11 | +1.2% | $9.10 | $9.99 | $9.09 | 7,266,500 | |
| $9.26 | +0.21 | +2.3% | $9.18 | $9.34 | $8.89 | 4,209,800 | |
| $9.05 | -0.16 | -1.7% | $9.12 | $9.18 | $8.92 | 3,422,800 | |
| $9.21 | -0.23 | -2.4% | $9.33 | $9.44 | $9.13 | 3,507,700 | |
| $9.44 | +0.58 | +6.5% | $9.07 | $9.58 | $8.93 | 7,107,633 | |
| $8.86 | -0.08 | -0.9% | $8.87 | $8.98 | $8.26 | 5,579,176 | |
| $8.94 | +0.52 | +6.2% | $8.44 | $9.20 | $8.44 | 10,441,300 | |
| $8.42 | -0.37 | -4.2% | $8.50 | $8.66 | $8.02 | 5,976,500 |
Splits
1 split · NASDAQ:NVAX · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-20 | Consolidation |
- Ticker
- Xetra:NVV1
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Xetra
- Currency
- EUR
What changed lately
Latest news release · Nov 11, 2026
Novavax to Participate in Jefferies London Healthcare Conference
Latest earnings call · Nov 5, 2026
Novavax (NASDAQ:NVAX) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 5, 2026
Q3 2026 Earnings Presentation
Earnings · 30 slides
Latest news
Novavax to Participate in Jefferies London Healthcare Conference
Nov 11, 2026
Closed $8.76 (-12.2%) on Nov 12, 2026
Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights
Nov 5, 2026
Closed $9.78 (-8.2%) on Nov 5, 2026
Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe
Oct 29, 2026
Closed $10.47 (+1.5%) on Oct 29, 2026
Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026
Oct 29, 2026
Closed $10.47 (+1.5%) on Oct 29, 2026
Novavax to Participate in September Investor Conferences
Sep 2, 2026
Closed $10.34 (+0.2%) on Sep 3, 2026
Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season
Aug 28, 2026
Closed $9.26 (+2.3%) on Aug 28, 2026
Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights
Aug 6, 2026
Closed $7.74 (+0.5%) on Aug 6, 2026
Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026
Jul 30, 2026
Closed $7.44 (+1.4%) on Jul 30, 2026
Novavax to Participate in 2026 Jefferies Global Healthcare Conference
Jun 1, 2026
Closed $10.21 (-2.9%) on Jun 2, 2026
Novavax to Participate in BofA Securities 2026 Health Care Conference
May 7, 2026
Closed $10.11 (+9.5%) on May 8, 2026
Novavax, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 18 in the last 12 months · 277 in all · newest Nov 11, 2026 · oldest 2019
- Calls
- 23 calls with a replay · 23 with a transcript · latest Nov 5, 2026
- Decks
- 73 decks · latest Nov 5, 2026
Where Novavax, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:NVAX · Home listing | NASDAQ | United States | USD |
| gettex:NVV1 | gettex | Germany | EUR |
| Tradegate:NVV1 | Tradegate | Germany | EUR |
| BOATS:NVAX | BOATS | United States | USD |
| LS Exchange:A2PKMZ | LS Exchange | Germany | EUR |
| BMV:NVAX | BMV | Mexico | MXN |
| Lang & Schwarz:A2PKMZ | Lang & Schwarz | Germany | EUR |
| Frankfurt:NVV1 | Frankfurt | Germany | EUR |
| LSIN:0A3S | LSIN | United Kingdom | USD |
| VIE:NVAX | Vienna | Austria | EUR |
| Dusseldorf:NVV1 | Dusseldorf | Germany | EUR |
| Stuttgart:NVV1 | Stuttgart | Germany | EUR |
| SIX Swiss:NVAX | SIX Swiss | Switzerland | CHF |
| BIVA:NVAX | BIVA | Mexico | MXN |
| BSESOF:NVV1 | BSESOF | Bulgaria | EUR |
| SIX Swiss:NVAX.USD | SIX Swiss | Switzerland | USD |
| BX Swiss:NVV1 | BX Swiss | Switzerland | CHF |
| Munich:NVV1 | Munich | Germany | EUR |
| Hamburg:NVV1 | Hamburg | Germany | EUR |
| Hanover:NVV1 | Hanover | Germany | EUR |
| Xetra:NVV1 · This page | Xetra | Germany | EUR |
Valuation
EV/sales 2.2× against a median of 28.1×: the lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $902.3M USD
- P/E
- Loss
- EV/sales
- 2.2×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- 77.3%
- Operating margin
- −21.2%
- Net margin
- −18.6%
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.98
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Novavax, Inc. · NASDAQ:NVAX | US$1.23B | US$902.3M | n/a | 2.2× | n/a | n/a | −18.6% | n/a | 1.98 |
| Avalyn Pharma Inc. · NASDAQ:AVLN | US$1.26B | US$946.4M | n/a | n/a | n/a | 3.4× | n/a | 0.0× | 0.12 |
| LB Pharmaceuticals Inc · NASDAQ:LBRX | US$1.26B | US$858.7M | n/a | n/a | n/a | 3.0× | n/a | 0.0× | 0.81 |
| MannKind Corporation · NASDAQ:MNKD | US$1.24B | US$1.46B | n/a | 3.5× | 309× | n/a | −18.1% | n/a | 1.06 |
| Silence Therapeutics PLC · NASDAQ:SLN | US$1.23B | US$984.6M | n/a | 2,159× | n/a | 5.7× | n/a | 0.0× | 1.07 |
| Ocular Therapeutix, Inc. · NASDAQ:OCUL | US$1.23B | US$774.9M | n/a | 15.4× | n/a | 2.8× | −648.6% | 0.2× | 1.35 |
| Generate Biomedicines, Inc. · NASDAQ:GENB | US$1.22B | US$895.6M | n/a | 28.1× | n/a | 3.2× | −637.0% | 0.2× | 1.90 |
| Taysha Gene Therapies, Inc. · NASDAQ:TSHA | US$1.21B | US$837.4M | n/a | 153× | n/a | 3.4× | n/a | 0.1× | 1.69 |
| Mineralys Therapeutics, Inc. · NASDAQ:MLYS | US$1.21B | US$585.1M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 1.39 |
| GH Research PLC · NASDAQ:GHRS | US$1.20B | US$841.0M | n/a | n/a | n/a | 3.4× | n/a | 0.0× | 1.28 |
| Vor Biopharma Inc. · NASDAQ:VOR | US$1.18B | US$697.4M | 0.9× | n/a | n/a | n/a | n/a | n/a | 1.25 |
| Median of the others | US$1.23B | US$849.9M | 0.9× | 28.1× | 309× | 3.3× | −637.0% | 0.0× | 1.27 |
Forecasts
5 strong buy · 1 hold · 2 sell · 1 strong sell · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 14.11 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.051 · 8 analysts
- Revenue, year to Dec 2026
- 473.1M · 8 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| John C. Jacobs | President and Chief Executive Officer |
| Jim Kelly | Executive Vice President, Chief Financial Officer and Treasurer |
| Mark Casey | Executive Vice President, Chief Legal Officer |
| Troy Morgan | Senior Vice President, Deputy General Counsel & Chief Compliance Officer |
| Elaine O’Hara | Executive Vice President, Chief Strategy Officer |
| Ian Watkins | Executive Vice President, Chief Human Resources Officer |
| Rick Crowley | Executive Vice President, Chief Operations Officer |
| Robert Walker | Executive Vice President, Head of Research & Development |
| Silvia Taylor | Executive Vice President, Chief Corporate Affairs Officer and Head of Novavax Sweden |
Board
| Director | Role |
|---|---|
| Charles Newton | Director |
| Gregg Alton | Director |
| John Shiver | Director |
| Rachel King | Director |
| Richard Douglas | Director |
| Rick Rodgers | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Novavax (NASDAQ:NVAX) Q3 2026 Earnings Call | Thu, Nov 05, 2026 · 8:30 AM ET | Replay |
| Novavax (NASDAQ:NVAX) Q2 2026 Earnings Call | Thu, Aug 06, 2026 · 8:30 AM ET | Replay |
| Novavax (NASDAQ:NVAX) Q1 2026 Earnings Call | Wed, May 06, 2026 · 8:30 AM ET | Replay |
| Novavax (NASDAQ:NVAX) Q4 2025 Earnings Call | Thu, Feb 26, 2026 · 8:30 AM ET | Replay |
| Novavax (NASDAQ:NVAX) Q3 2025 Earnings Call | Thu, Nov 06, 2025 · 8:30 AM ET | Replay |
| Novavax (NASDAQ:NVAX) Q2 2025 Earnings Call | Wed, Aug 06, 2025 · 8:30 AM ET | Replay |
| Novavax (NASDAQ:NVAX) Q1 2025 Earnings Call | Thu, May 08, 2025 · 8:30 AM ET | Replay |
| Novavax (NASDAQ:NVAX) Q4 2024 Earnings Call | Thu, Feb 27, 2025 · 8:00 AM ET | Replay |
| Novavax (NASDAQ:NVAX) Q3 2024 Earnings Call | Tue, Nov 12, 2024 · 8:30 AM ET | Replay |
| Novavax (NASDAQ:NVAX) Q2 2024 Earnings Call | Thu, Aug 08, 2024 · 11:30 AM ET | Replay |
All 23 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · Before open | −8.2% |
| Q2 2026 | Aug 6, 2026 · Before open | +0.5% |
| Q1 2026 | May 6, 2026 · Before open | +15.6% |
| Q4 2025 | Feb 26, 2026 | +6.4% |
| Q3 2025 | Nov 6, 2025 · Before open | −1.3% |
| Q2 2025 | Aug 6, 2025 · Before open | +12.6% |
| Q1 2025 | May 8, 2025 · Before open | +11.9% |
| Q4 2024 | Feb 26, 2025 · Before open | +2.1% |
| Q3 2024 | Nov 12, 2024 · Before open | −6.1% |
| Q2 2024 | Aug 8, 2024 · Before open | +9.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 10, 2024 · Before open | +98.7% |
| Q4 2023 | Feb 28, 2024 · Before open | −26.7% |
| Q3 2023 | Nov 9, 2023 · Before open | −1.3% |
| Q2 2023 | Aug 8, 2023 · Before open | −3.9% |
| Q1 2023 | May 9, 2023 · Before open | +27.8% |
| Q4 2022 | Feb 28, 2023 · After close | −25.9% |
| Q3 2022 | Nov 8, 2022 · After close | −5.2% |
| Q2 2022 | Aug 8, 2022 · After close | −29.6% |
| Q1 2022 | May 9, 2022 · After close | +1.1% |
| Q4 2021 | Feb 28, 2022 · After close | +0.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 30 slides | Nov 5, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 29 slides | Aug 6, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 34 slides | May 6, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 35 slides | Feb 26, 2026 |
| J.P. Morgan Healthcare Conference 2026 | Conference | 15 slides | Jan 12, 2026 |
| Goldman Sachs 46th Annual Global Healthcare Conference (June 2025) | Conference | 24 slides | Jun 11, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 18 slides | May 8, 2025 |
| Investor Presentation (March 2025) | Investor deck | 41 slides | Mar 4, 2025 |
| Q4 2024 Earnings Presentation | Earnings | 20 slides | Feb 27, 2025 |
| Investor Presentation (January 2025) | Investor deck | 42 slides | Jan 13, 2025 |
Show 50 decks
This page holds 50 of 73 decks. Open Decks
Financings
| Raise | Date |
|---|---|
| 4.625% Convertible Senior Notes due 2031 Announced: about US$49.7M | Aug 21, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.12B | 682.2M | 983.7M | 1.98B | 1.15B | 475.6M | 18.7M | 34.3M | 31.2M | 15.4M |
| Cost of revenue | 73.0M | 202.7M | 343.8M | 902.6M | 0 | 0 | 113.8M | 173.8M | 168.4M | 237.9M |
| Gross profit | 1.05B | 479.4M | 212.6M | 696.3M | 1.15B | 475.6M | -95.2M | 34.3M | 31.2M | -222.6M |
| Research and development | 342.3M | 391.2M | 737.5M | 1.24B | 2.53B | 747.0M | 113.8M | 173.8M | 168.4M | 237.9M |
| Selling, general and administrative | 157.5M | 337.2M | 468.9M | 488.7M | 298.4M | 145.3M | 34.4M | 34.4M | 34.5M | 46.5M |
| Operating income | 452.8M | -248.9M | -566.5M | -644.7M | -1.69B | -416.7M | -120.6M | -173.9M | -171.7M | -269.1M |
| Depreciation and amortization | 28.0M | 48.0M | 41.0M | 29.0M | 13.0M | 4.30M | 5.10M | 7.40M | 7.60M | 7.70M |
| EBITDA | 480.8M | -200.9M | -525.5M | -615.7M | -1.67B | -412.4M | -115.5M | -166.5M | -164.1M | -261.4M |
| Interest expense | 22.5M | 20.1M | 14.4M | 19.9M | 21.1M | 15.1M | 13.6M | 13.6M | 14.1M | 13.0M |
| Income before tax | 442.2M | -176.6M | -543.0M | -653.6M | -1.71B | -418.3M | -132.7M | -184.7M | -183.8M | -280.0M |
| Income tax | 1.86M | 10.9M | 2.03M | 4.29M | 29.2M | 0 | 0 | 1.36M | 2.31M | 2.32M |
| Net income | 440.3M | -187.5M | -545.1M | -657.9M | -1.74B | -418.3M | -132.7M | -184.7M | -183.8M | -280.0M |
| Earnings per share, basic | 2.72 | -1.23 | -5.41 | -8.42 | -23.44 | -7.27 | -5.51 | -9.99 | -12.56 | -1.03 |
| Earnings per share, diluted | 2.58 | -1.23 | -5.41 | -8.42 | -23.44 | -7.27 | -5.51 | -9.99 | -12.56 | -1.03 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 240.6M | 530.2M | 568.5M | 1.34B | 1.52B | 553.4M | 78.8M | 70.2M | 106.3M | 144.4M |
| Short-term investments | 494.4M | 392.9M | 0 | 0 | 157.6M | 0 | 22.0M | 51.0M | 91.1M | |
| Receivables | 106.4M | 108.3M | 297.2M | 82.4M | 455.0M | 262.0M | 7.50M | -70.3M | 37.9M | 233.0K |
| Inventory | 11.5M | 8.75M | 41.7M | 36.7M | 8.87M | -166.7M | -83.0M | 12.0M | 13.1M | 15.7M |
| Current assets | 978.3M | 1.13B | 1.14B | 1.70B | 2.16B | 1.25B | 97.2M | 119.3M | 203.3M | 287.8M |
| Property, plant and equipment | 44.8M | 138.4M | 305.8M | 294.2M | 225.7M | 180.0M | 11.4M | 28.4M | 36.0M | 40.2M |
| Goodwill | 113.5M | 107.5M | 127.5M | 126.3M | 131.5M | 135.4M | 51.2M | 52.0M | 53.6M | 51.7M |
| Total assets | 1.18B | 1.56B | 1.80B | 2.26B | 2.58B | 1.58B | 173.0M | 208.0M | 302.5M | 394.3M |
| Accounts payable | 24.6M | 41.6M | 132.6M | 216.5M | 127.0M | 54.3M | 2.91M | 9.30M | 5.61M | 5.68M |
| Current liabilities | 459.9M | 1.15B | 1.64B | 2.46B | 2.39B | 579.7M | 25.8M | 45.5M | 73.7M | 66.4M |
| Long-term debt | 244.2M | 169.7M | 168.0M | 166.5M | 323.5M | 322.0M | 320.6M | 319.2M | 317.8M | 316.3M |
| Total debt | 244.2M | 230.4M | 229.1M | 549.8M | 454.0M | 322.0M | 321.9M | 343.8M | 352.5M | 345.9M |
| Total liabilities | 1.30B | 2.18B | 2.51B | 2.89B | 2.93B | 955.3M | 359.0M | 375.9M | 404.2M | 399.8M |
| Shareholders' equity | -127.8M | -623.8M | -716.9M | -634.1M | -351.7M | 627.2M | -186.0M | -167.9M | -101.7M | -5.55M |
| Shares outstanding | 162.6M | 160.4M | 139.5M | 86.0M | 75.8M | 71.0M | 32.4M | 19.2M | 323.2M | 271.2M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -244.6M | -87.3M | -714.0M | -415.9M | 322.9M | -42.5M | -136.6M | -184.8M | -144.5M | -258.8M |
| Capital spending | -5.56M | -13.1M | -58.8M | -93.0M | -57.5M | -54.6M | -1.86M | -1.37M | -4.19M | -18.2M |
| Free cash flow | -250.2M | -100.3M | -772.8M | -508.9M | 265.5M | -97.2M | -138.5M | -186.2M | -148.7M | -277.0M |
| Cash from investing | -78.3M | -204.0M | -58.8M | -93.0M | 100.2M | -377.8M | 38.5M | 28.6M | 36.0M | 28.0M |
| Cash from financing | 27.7M | 260.6M | 4.47M | 325.0M | 461.7M | 984.8M | 98.4M | 102.8M | 64.5M | 279.8M |
| Dividends paid | -39.1M | 0 | 0 | |||||||
| Share buybacks | -4.80M | 589.6M | -39.1M | 98.4M | 102.8M | 64.6M | 3.80M | |||
| Change in cash | -289.2M | -38.5M | -765.0M | -179.4M | 879.5M | 566.6M | 221.0K | -53.5M | -43.8M | 48.8M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Nov 10, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| 8-K · Current report | Oct 29, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 7, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Aug 6, 2026 | Offer document | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 23, 2026 | Meeting outcome | SEC |
| 144 · Notice of proposed sale | May 27, 2026 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | May 7, 2026 | Other filings | SEC |
| 8-K · Current report | May 6, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 6, 2026 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 30, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 27, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 27, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 27, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 27, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 16, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 16, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 8, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Mar 9, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Mar 9, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Mar 9, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Mar 9, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 26, 2026 | Results | SEC |
| 10-K · Annual report | Feb 26, 2026 | Annual report | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 11, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 9, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 20, 2026 | Material contract | SEC |
| 8-K · Current report | Jan 12, 2026 | Results | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 12, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2025 | Current report | SEC |
| 4 · Change in ownership | Oct 30, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 22, 2025 | Material contract | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Oct 7, 2025 | Current report | SEC |
| 8-K · Current report | Aug 27, 2025 | Material contract | SEC |
| 8-K · Current report | Aug 27, 2025 | Current report | SEC |
| 8-K · Current report | Aug 21, 2025 | Material contract | SEC |
| 8-K · Current report | Aug 6, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 6, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 24, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 11, 2025 | Current report | SEC |
| 8-K · Current report | May 27, 2025 | Management or board change | SEC |
| 144 · Notice of proposed sale | May 19, 2025 | Other filings | SEC |
| 8-K · Current report | May 19, 2025 | Current report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 5, 2025 | Material contract | SEC |
| DEFA14A · Additional proxy material | Apr 30, 2025 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 29, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 29, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 29, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 29, 2025 | Insider trade | SEC |
| 8-K · Current report | Apr 29, 2025 | Management or board change | SEC |
| 8-K · Current report | Apr 23, 2025 | Current report | SEC |
| 144 · Notice of proposed sale | Apr 14, 2025 | Other filings | SEC |
| 8-K · Current report | Apr 2, 2025 | Current report | SEC |
| 4 · Change in ownership | Mar 12, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 12, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 11, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Mar 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 11, 2025 | Current report | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 4, 2025 | Current report | SEC |
| 8-K · Current report | Feb 27, 2025 | Results | SEC |
| 10-K · Annual report | Feb 27, 2025 | Annual report | SEC |
| 4 · Change in ownership | Feb 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 13, 2025 | Results | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2025 | Insider trade | SEC |
| 144/A · Notice of proposed sale, amended | Jan 2, 2025 | Other filings | SEC |
| 8-K · Current report | Dec 30, 2024 | Acquisition or disposal | SEC |
| 144 · Notice of proposed sale | Dec 26, 2024 | Other filings | SEC |
| 8-K · Current report | Dec 18, 2024 | Material contract | SEC |
| 4 · Change in ownership | Dec 13, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 13, 2024 | Other filings | SEC |
| 8-K · Current report | Dec 4, 2024 | Material contract | SEC |
| 8-K · Current report | Nov 19, 2024 | Current report | SEC |
| 4 · Change in ownership | Nov 13, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 13, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Current report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| 8-K · Current report | Nov 5, 2024 | Material contract | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 4, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 16, 2024 | Current report | SEC |
| 8-K · Current report | Oct 2, 2024 | Current report | SEC |
| 144 · Notice of proposed sale | Sep 18, 2024 | Other filings | SEC |
| 4 · Change in ownership | Aug 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2024 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Aug 8, 2024 | Offer document | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| SC 13G/A · Big-stake notice, amended | Jul 10, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Jun 20, 2024 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Jun 18, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 17, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 14, 2024 | Management or board change | SEC |
| 8-K · Current report | Jun 6, 2024 | Current report | SEC |
| DEFA14A · Additional proxy material | Jun 4, 2024 | Meeting notice | SEC |
| 8-K · Current report | May 23, 2024 | Management or board change | SEC |
| DFAN14A | May 20, 2024 | Other filings | SEC |
| SC 13D/A · Big-stake notice, amended | May 20, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | May 15, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 14, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 14, 2024 | Other filings | SEC |
| DFAN14A | May 13, 2024 | Other filings | SEC |
| 8-K · Current report | May 13, 2024 | Material contract | SEC |
| 8-K · Current report | May 10, 2024 | Results | SEC |
| 10-Q · Quarterly report | May 10, 2024 | Quarterly report | SEC |
| DFAN14A | May 8, 2024 | Other filings | SEC |
| DFAN14A | May 7, 2024 | Other filings | SEC |
| SC 13D/A · Big-stake notice, amended | May 7, 2024 | Big-stake notice | SEC |
| DFAN14A | May 6, 2024 | Other filings | SEC |
| PREC14A | May 6, 2024 | Other filings | SEC |
| ARS · Annual report to shareholders | Apr 29, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2024 | Meeting notice | SEC |
| 8-K · Current report | Apr 26, 2024 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Apr 15, 2024 | Big-stake notice | SEC |
| SC 13D · Big-stake notice | Apr 15, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 26, 2024 | Material contract | SEC |
| 4 · Change in ownership | Mar 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2024 | Insider trade | SEC |
This page holds 200 of 1,002 filings. Open Filings
Cap table
Built by 6ix from Novavax, Inc.’s releases · as of Oct 31, 2026
- Common shares
- 165,009,009
- Fully diluted
- 165,009,009
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 165,009,009 | Oct 31, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 31, 2026 | 165,009,009 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| David Mott Other companies: Mersana Therapeutics Inc (Director · Since at least Jun 27, 2017); Ardelyx, Inc. (Chairman · Since at least Jun 18, 2014); Enliven Therapeutics, Inc. (Director · Mar 11, 2020 – Jun 2, 2022 · Past); Nightstar Therapeutics PLC (Director · Jan 1, 2019 – Jun 7, 2019 · Past); Adaptimmune Therapeutics PLC (Director · Jan 1, 2016 – Jul 1, 2024 · Past); Epizyme Inc (Director · May 30, 2013 – Aug 12, 2022 · Past); Omthera Pharmaceuticals Inc (Director · Apr 11, 2013 – Jul 18, 2013 · Past); Tesaro Inc (Director · Jun 27, 2012 – Jan 22, 2019 · Past); Medimmune Inc (Vice Chair. of the Board, CEO, Director · Feb 23, 2006 – Jun 18, 2007 · Past) | Director · Since at least Jun 16, 2020 |
| Gail K. Boudreaux Other companies: Target Corporation (Director · Since at least Sep 23, 2021); Elevance Health, Inc. (President and CEO · Since at least Nov 20, 2017); Zimmer Biomet Holdings, Inc. (Director · Dec 10, 2012 – Mar 31, 2021 · Past); Xcel Energy Inc. (Director · Mar 1, 2012 – Dec 28, 2017 · Past); UnitedHealth Group Incorporated (EVP & CEO, UnitedHealthcare · May 5, 2008 – Sep 23, 2014 · Past); Genzyme Corp (Director · May 25, 2006 – Apr 4, 2011 · Past) | Director · Jun 17, 2015 – Mar 16, 2017 · Past |
| Richard Rodgers Other companies: Opus Genetics, Inc. (Director · Since at least Dec 2, 2014); Ardelyx, Inc. (Director · Since at least Jun 18, 2014); Sagimet Biosciences Inc. - Series A (Director · Jul 13, 2023 – Jul 18, 2023 · Past); Tesaro Inc (Executive VP & CFO · Jun 27, 2012 – Mar 6, 2013 · Past); Abraxis BioScience Inc (Senior Vice President and CFO · Jul 9, 2009 – Jul 13, 2009 · Past); Mgi Pharma Inc (Sr. VP and Controller · Jul 15, 2006 – Jan 28, 2008 · Past) | Director · Since at least Oct 29, 2022 |
| Charles Newton Other companies: Keros Therapeutics, Inc. (Director · Since at least Feb 26, 2026); Coherus Oncology, Inc. (Director · Since at least May 4, 2022); Lyell Immunopharma, Inc. (Chief Financial Officer · Since at least Jun 16, 2021); 2Seventy Bio Inc (Director · Mar 20, 2024 – May 13, 2025 · Past) | Director · Since at least Apr 25, 2025 |
| Gregory F Covino Other companies: Tesaro Inc (SVP, CAO, PAO · Aug 13, 2018 – Jan 22, 2019 · Past); Biogen Inc. (VP, Chief Accounting Officer · May 1, 2012 – Mar 1, 2018 · Past); Hubbell Inc (Vice President, Controller · Dec 4, 2006 – Dec 6, 2007 · Past) | EVP, Chief Financial Officer · Nov 16, 2020 – Nov 16, 2020 · Past |
| Margaret G McGlynn Other companies: Amicus Therapeutics Inc (Director · Since at least Oct 28, 2009); Vertex Pharmaceuticals Incorporated (Director · May 12, 2011 – May 1, 2023 · Past); Air Products and Chemicals, Inc. (Director · Dec 31, 2005 – Sep 30, 2020 · Past) | Director · Since at least Dec 7, 2020 |
| Mark Casey Other companies: Mallinckrodt Inc (EVP & Chief Legal Officer · Feb 1, 2018 – Jun 16, 2022 · Past); Aceragen Inc. (Senior VP & General Counsel · Jun 29, 2015 – Jan 3, 2018 · Past); Hologic Inc (SVP, CAO, GC & Secretary · Jan 11, 2008 – Nov 18, 2014 · Past) | Executive Vice President, Chief Legal Officer · Since at least Dec 11, 2023 |
| James Patrick Kelly Other companies: Supernus Pharmaceuticals, Inc. (Executive Vice-President & CFO · Oct 12, 2020 – Feb 19, 2021 · Past); Vanda Pharmaceuticals Inc. (EVP & Chief Financial Officer · Jan 2, 2020 – Mar 2, 2020 · Past) | EVP, CFO and Treasurer · Since at least Aug 16, 2021 |
| Rachel King Other companies: Fulcrum Therapeutics, Inc. (Board Member · Since at least Nov 12, 2024); Crescent Biopharma, Inc. (Director · Jan 7, 2016 – May 1, 2024 · Past) | Director · Since at least Oct 31, 2018 |
| Richard H. Douglas Other companies: Aldeyra Therapeutics, Inc. (Director · Since at least Jun 10, 2026); MaxCyte, Inc. (Director · Since at least Dec 22, 2024) | Director · Since at least Jun 20, 2026 |
All 28 people
| Person | Seat |
|---|---|
| Ian Watkins Other companies: Mallinckrodt Inc (See Remarks · Nov 11, 2020 – Jun 16, 2022 · Past) | Executive Vice President, Chief Human Resources Officer · Since at least Nov 5, 2026 |
| John C. Jacobs Other companies: Harmony Biosciences Holdings, Inc. (PRESIDENT, CEO, Director · Aug 18, 2020 – Aug 15, 2022 · Past) | President and Chief Executive Officer · Since at least Jan 23, 2023 |
| John Shiver Other companies: Icosavax Inc (Director · Jan 3, 2022 – Jun 6, 2023 · Past) | Director · Since at least Mar 10, 2025 |
| Dennis W Genge | VP, Treasurer,CFO · Feb 17, 2006 – Feb 17, 2006 · Past |
| Elaine O’Hara | Executive Vice President, Chief Strategy Officer · Since at least Nov 5, 2026 |
| Gregg Alton | Director · Since at least Jun 20, 2026 |
| Jim Kelly | Executive Vice President, Chief Financial Officer and Treasurer · Since at least Jun 1, 2026 |
| Jim Robinson | VP, Technical & Quality Ops. · Aug 2, 2007 – Mar 5, 2009 · Past |
| John A Herrmann III | EVP, Chief Legal Officer · Jul 31, 2015 – Dec 14, 2023 · Past |
| John O Marsh Jr | Director · Feb 17, 2006 – Mar 6, 2014 · Past |
| Rajiv I Modi | Director · Mar 31, 2009 – Jun 16, 2015 · Past |
| Raymond Joseph Hage | Sr. VP. Commercial Operations · May 4, 2005 – Jul 1, 2009 · Past |
| Rick Crowley | Executive Vice President, Chief Operations Officer · Since at least Nov 4, 2026 |
| Rick Rodgers | Director · Since at least Jun 23, 2026 |
| Robert Walker | EVP, R&D · Since at least Mar 30, 2026 |
| Silvia Taylor | Executive Vice President, Chief Corporate Affairs Officer and Head of Novavax Sweden · Since at least Nov 5, 2026 |
| Timothy Jon Hahn | SVP, Manufacturing · Jun 10, 2013 – Mar 5, 2015 · Past |
| Troy Morgan | Senior Vice President, Deputy General Counsel & Chief Compliance Officer · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Novavax, Inc.